Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why

Core Viewpoint - Insmed Incorporated (NASDAQ:INSM) is highlighted as a promising high-growth healthcare stock, with a price target increase to $208 from $205 by Stifel, indicating strong confidence in the company's future performance [1]. Financial Performance - Insmed reported total revenues of $606.4 million for the full year 2025, with BRINSUPRI contributing $172.7 million and $144.6 million in Q4 [2]. - ARIKAYCE generated $119.2 million in Q4 and $433.8 million for the full year, reflecting a 19% annual growth and surpassing the upper end of guidance [2]. - The combination of increasing commercial uptake and expanding market opportunities suggests that 2026 could be a significant turning point for revenue visibility and operating leverage [2]. Company Overview - Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey, focusing on developing and commercializing therapies for rare and serious diseases [3]. - Key assets include brensocatib and Treprostinil Palmitil Inhalation Powder [3].